Cargando…
Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials
Retinal and optic nerve diseases are degenerative ocular pathologies which lead to irreversible visual loss. Since the advanced therapies availability, cell-based therapies offer a new all-encompassing approach. Advances in the knowledge of neuroprotection, immunomodulation and regenerative properti...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120242/ https://www.ncbi.nlm.nih.gov/pubmed/27928464 http://dx.doi.org/10.4252/wjsc.v8.i11.376 |
_version_ | 1782469200860676096 |
---|---|
author | Labrador-Velandia, Sonia Alonso-Alonso, María Luz Alvarez-Sanchez, Sara González-Zamora, Jorge Carretero-Barrio, Irene Pastor, José Carlos Fernandez-Bueno, Iván Srivastava, Girish Kumar |
author_facet | Labrador-Velandia, Sonia Alonso-Alonso, María Luz Alvarez-Sanchez, Sara González-Zamora, Jorge Carretero-Barrio, Irene Pastor, José Carlos Fernandez-Bueno, Iván Srivastava, Girish Kumar |
author_sort | Labrador-Velandia, Sonia |
collection | PubMed |
description | Retinal and optic nerve diseases are degenerative ocular pathologies which lead to irreversible visual loss. Since the advanced therapies availability, cell-based therapies offer a new all-encompassing approach. Advances in the knowledge of neuroprotection, immunomodulation and regenerative properties of mesenchymal stem cells (MSCs) have been obtained by several preclinical studies of various neurodegenerative diseases. It has provided the opportunity to perform the translation of this knowledge to prospective treatment approaches for clinical practice. Since 2008, several first steps projecting new treatment approaches, have been taken regarding the use of cell therapy in patients with neurodegenerative pathologies of optic nerve and retina. Most of the clinical trials using MSCs are in I/II phase, recruiting patients or ongoing, and they have as main objective the safety assessment of MSCs using various routes of administration. However, it is important to recognize that, there is still a long way to go to reach clinical trials phase III-IV. Hence, it is necessary to continue preclinical and clinical studies to improve this new therapeutic tool. This paper reviews the latest progress of MSCs in human clinical trials for retinal and optic nerve diseases. |
format | Online Article Text |
id | pubmed-5120242 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-51202422016-12-08 Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials Labrador-Velandia, Sonia Alonso-Alonso, María Luz Alvarez-Sanchez, Sara González-Zamora, Jorge Carretero-Barrio, Irene Pastor, José Carlos Fernandez-Bueno, Iván Srivastava, Girish Kumar World J Stem Cells Minireviews Retinal and optic nerve diseases are degenerative ocular pathologies which lead to irreversible visual loss. Since the advanced therapies availability, cell-based therapies offer a new all-encompassing approach. Advances in the knowledge of neuroprotection, immunomodulation and regenerative properties of mesenchymal stem cells (MSCs) have been obtained by several preclinical studies of various neurodegenerative diseases. It has provided the opportunity to perform the translation of this knowledge to prospective treatment approaches for clinical practice. Since 2008, several first steps projecting new treatment approaches, have been taken regarding the use of cell therapy in patients with neurodegenerative pathologies of optic nerve and retina. Most of the clinical trials using MSCs are in I/II phase, recruiting patients or ongoing, and they have as main objective the safety assessment of MSCs using various routes of administration. However, it is important to recognize that, there is still a long way to go to reach clinical trials phase III-IV. Hence, it is necessary to continue preclinical and clinical studies to improve this new therapeutic tool. This paper reviews the latest progress of MSCs in human clinical trials for retinal and optic nerve diseases. Baishideng Publishing Group Inc 2016-11-26 2016-11-26 /pmc/articles/PMC5120242/ /pubmed/27928464 http://dx.doi.org/10.4252/wjsc.v8.i11.376 Text en ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Minireviews Labrador-Velandia, Sonia Alonso-Alonso, María Luz Alvarez-Sanchez, Sara González-Zamora, Jorge Carretero-Barrio, Irene Pastor, José Carlos Fernandez-Bueno, Iván Srivastava, Girish Kumar Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials |
title | Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials |
title_full | Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials |
title_fullStr | Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials |
title_full_unstemmed | Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials |
title_short | Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials |
title_sort | mesenchymal stem cell therapy in retinal and optic nerve diseases: an update of clinical trials |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120242/ https://www.ncbi.nlm.nih.gov/pubmed/27928464 http://dx.doi.org/10.4252/wjsc.v8.i11.376 |
work_keys_str_mv | AT labradorvelandiasonia mesenchymalstemcelltherapyinretinalandopticnervediseasesanupdateofclinicaltrials AT alonsoalonsomarialuz mesenchymalstemcelltherapyinretinalandopticnervediseasesanupdateofclinicaltrials AT alvarezsanchezsara mesenchymalstemcelltherapyinretinalandopticnervediseasesanupdateofclinicaltrials AT gonzalezzamorajorge mesenchymalstemcelltherapyinretinalandopticnervediseasesanupdateofclinicaltrials AT carreterobarrioirene mesenchymalstemcelltherapyinretinalandopticnervediseasesanupdateofclinicaltrials AT pastorjosecarlos mesenchymalstemcelltherapyinretinalandopticnervediseasesanupdateofclinicaltrials AT fernandezbuenoivan mesenchymalstemcelltherapyinretinalandopticnervediseasesanupdateofclinicaltrials AT srivastavagirishkumar mesenchymalstemcelltherapyinretinalandopticnervediseasesanupdateofclinicaltrials |